Zuzana Saidak1,2, Mony Chenda Morisse2,3, Denis Chatelain2,4, Chloé Sauzay2,3, Aline Houessinon2,5, Nelly Guilain4, Marion Soyez3, Bruno Chauffert2,5, Stéphanie Dakpé2,6, Antoine Galmiche7,3. 1. Department of Molecular Oncobiology, CHU Sud, Amiens, France. 2. CHIMERE team, University of Picardie Jules Verne, Amiens, France. 3. Department of Biochemistry, CHU Sud, Amiens, France. 4. Department of Pathology, CHU Nord, Amiens, France. 5. Department of Medical Oncology, CHU Sud, Amiens, France. 6. Department of Maxillofacial Surgery, CHU Sud, Amiens, France. 7. CHIMERE team, University of Picardie Jules Verne, Amiens, France Galmiche.Antoine@chu-amiens.fr.
Abstract
BACKGROUND/AIM: The squamous cell carcinoma antigen (SCCA), encoded by the genes SERPINB3/B4, is a tumour marker produced by head and neck squamous cell carcinoma (HNSCC). We aimed to examine SERPINB3/B4 mRNA levels and its clinical significance in the therapeutic context. MATERIALS AND METHODS: We retrieved mRNA expression levels, clinical, pathological and genomic data for 520 HNSCC from The Cancer Genome Atlas (TCGA). RESULTS: HNSCC tumours express high levels of SERPINB3/B4 mRNA. SERPINB3 expression differs depending on Human papillomavirus (HPV) infection status, primary tumour location, grade and differentiation, extension to lymph nodes and extracapsular spread. Interestingly, we observed an association between SERPINB3/B4 and the presence of tumour immune infiltrate as well as the expression of the immune checkpoint regulators PD-L1/PD-L2 that depended on HPV status. CONCLUSION: Our findings point to potential interest of SERPINB3/B4 for the stratification of HNSCC patients in the therapeutic context. Copyright
BACKGROUND/AIM: The squamous cell carcinoma antigen (SCCA), encoded by the genes SERPINB3/B4, is a tumour marker produced by head and neck squamous cell carcinoma (HNSCC). We aimed to examine SERPINB3/B4 mRNA levels and its clinical significance in the therapeutic context. MATERIALS AND METHODS: We retrieved mRNA expression levels, clinical, pathological and genomic data for 520 HNSCC from The Cancer Genome Atlas (TCGA). RESULTS:HNSCC tumours express high levels of SERPINB3/B4 mRNA. SERPINB3 expression differs depending on Human papillomavirus (HPV) infection status, primary tumour location, grade and differentiation, extension to lymph nodes and extracapsular spread. Interestingly, we observed an association between SERPINB3/B4 and the presence of tumour immune infiltrate as well as the expression of the immune checkpoint regulators PD-L1/PD-L2 that depended on HPV status. CONCLUSION: Our findings point to potential interest of SERPINB3/B4 for the stratification of HNSCC patients in the therapeutic context. Copyright
Authors: Karam El-Bayoumy; Neil D Christensen; Jiafen Hu; Raphael Viscidi; Douglas B Stairs; Vonn Walter; Kun-Ming Chen; Yuan-Wan Sun; Joshua E Muscat; John P Richie Journal: Cancer Prev Res (Phila) Date: 2020-05-20
Authors: Camille Jacqueline; Amanda Lee; Nolan Frey; Jonathan S Minden; Olivera J Finn Journal: Cancer Immunol Res Date: 2020-05-28 Impact factor: 11.151
Authors: Jeroen E van Schaik; Anna C Muller Kobold; Bernard F A M van der Laan; Bert van der Vegt; Bettien M van Hemel; Boudewijn E C Plaat Journal: Head Neck Date: 2019-03-04 Impact factor: 3.147